{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:49:34Z","timestamp":1768927774780,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.eprac.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:59:57Z","timestamp":1718233197000},"page":"810-816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26\u00a0Weeks Treatment"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1595-9906","authenticated-orcid":false,"given":"Elena A.","family":"Christofides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Stankiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Denham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Franek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Nakhle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"\u0141ukaszewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"C\u00f3zar-Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Kosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Kara\u015b","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fitz-Patrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Oroszl\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lillestol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Ovalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2024.06.002_bib2","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of Care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2024.06.002_bib3","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2024.06.002_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc23-Sint","article-title":"Introduction and methodology: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2024.06.002_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.06.002_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199307293290502","article-title":"The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus","volume":"329","author":"Reichard","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.06.002_bib7","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The Management of type 1 diabetes in adults. A Consensus Report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2024.06.002_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3810\/pgm.2011.07.2300","article-title":"Basal insulin: physiology, pharmacology, and clinical implications","volume":"123","author":"Niswender","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.eprac.2024.06.002_bib9","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2024.06.002_bib10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2337\/dci18-0019","article-title":"Insulin access and affordability Working group: Conclusions and Recommendations","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2024.06.002_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/dom.13904","article-title":"Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: results of the INSTRIDE 3 phase 3 switch study","volume":"22","author":"Blevins","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2024.06.002_bib14","first-page":"469","article-title":"The economics of biosimilars","volume":"6","author":"Blackstone","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.eprac.2024.06.002_bib15","first-page":"3","article-title":"Biosimilar cost Savings in the United States: Initial experience and Future Potential","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"},{"key":"10.1016\/j.eprac.2024.06.002_bib22","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1111\/dom.15281","article-title":"Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin\u00ae), lispro (prandilin\u00ae) and glargine (basalin\u00ae) with EU- und US-sourced reference insulins","volume":"25","author":"Chen","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2024.06.002_bib24","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.4155\/bio.12.185","article-title":"Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development","volume":"4","author":"Cai","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.eprac.2024.06.002_bib26","first-page":"497","article-title":"Recombinant human erythropoietins, biosimilars and immunogenicity","volume":"21","author":"Schellekens","year":"2008","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.eprac.2024.06.002_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/dme.13400","article-title":"Introduction of biosimilar insulins in Europe","volume":"34","author":"Davies","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.eprac.2024.06.002_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00005-012-0189-7","article-title":"Immunogenicity to biologics: mechanisms, prediction and reduction","volume":"60","author":"Sethu","year":"2012","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.eprac.2024.06.002_bib30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dom.14674","article-title":"Immunogenicity of LY2963016 insulin glargine and Lantus\u00ae insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus","volume":"24","author":"Wang","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2024.06.002_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/clim.2002.5220","article-title":"Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study","volume":"103","author":"Eibl","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.eprac.2024.06.002_bib32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4155\/bio-2020-0143","article-title":"Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?","volume":"12","author":"Jordan","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.eprac.2024.06.002_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/cer-2019-0136","article-title":"Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus(\u00ae)): a randomized open-label clinical trial","volume":"9","author":"Karonova","year":"2020","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.eprac.2024.06.002_bib34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11892-013-0411-y","article-title":"Hypoglycemia in patients with type 1 diabetes: epidemiology, pathogenesis, and prevention","volume":"13","author":"Awoniyi","year":"2013","journal-title":"Curr Diabetes Rep"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24005536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24005536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T17:58:39Z","timestamp":1725299919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24005536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1530891X24005536"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.06.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26\u00a0Weeks Treatment","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}